SEC Form DFiling only, no announcement found
Crosslink Therapeutics, based in Boston, MA, reported $5,500,000 sold in a private offering of options or warrants, with the first sale on October 8, 2026, in a Form D filed with the SEC on October 20, 2026. The filing says 8 investors have already invested.
Legal name on the filing: Crosslink Therapeutics Inc..
| Amount sold | $5,500,000Basis: Form D total amount sold, as of the filing of October 20, 2026. Not the announced round size. |
|---|---|
| Total offering | $5,500,000The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $0 |
| Securities offered | Option, warrant or other right to acquire another security; Security to be acquired upon exercise of option, warrant or other right |
| Exemption claimed | Rule 506(b) |
| Date of first sale | October 8, 2026 |
| Investors already invested | 8 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Pharmaceuticals |
| Principal place of business | Boston, MA |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | 2021 |
| Revenue range | Decline to Disclose |
| SEC CIK | 2067583 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Ronald D. Seidel, III | Executive Officer, Director | None linked |
| Andrew King | Director | None linked |
| Lou Tartaglia | Director | None linked |
| Rodolfo Chaparro | Director | None linked |
| David Fallace | Director | None linked |
| Cameron Gallagher | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Oct 20, 2026 | D (original) | $5,500,000 | $5,500,000 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through October 23, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Crosslink Therapeutics: SEC Form D deal record", https://vcbeast.com/deals/crosslink-therapeutics-form-d-2026-10-08. Source: SEC EDGAR, accession 0002067583-26-000002.